DTIL — Precision Biosciences Share News
0.000.00%
Last trade - 00:00- $183.27m
- $118.15m
- $34.26m
Precision BioSciences Inc reports results for the quarter ended March 31 - Earnings Summary
Brief: Precision Biosciences Q1 Income From Operations USD -22.112 Million
Precision BioSciences Inc expected to post a loss of $1.72 a share - Earnings Preview
Brief: Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Brief: Precision Biosciences Receives U.S. FDA Fast Track Designation For Pbgene-Hbv
Precision BioSciences Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Precision Biosciences Reports Fourth Quarter And FY 2024 Results
Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview
Precision BioSciences Inc expected to post a loss of $1.96 a share - Earnings Preview
Brief: Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv
Brief: Precision Biosciences Expects Cash Runway Into H2 2026
Brief: Precision Biosciences Receives Approval In Hong Kong To Expand Pbgene-Hbv Phase 1 Eliminate-B Trial
Brief: Precision Biosciences Highlights Preclinical Data, Outlines Design Of First-In-Human Clinical Trial For PBGENE-HBV
Precision BioSciences Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Precision BioSciences Reports Q3 Financial Results And Provides Business Update
Precision BioSciences Inc expected to post a loss of $1.92 a share - Earnings Preview
Brief: Precision Biosciences Strengthens Senior Leadership Team Ahead Of Anticipated Pbgene-HBV Clinical Execution
Brief: Precision BioSciences Receives $13 Million in Proceeds from Imugene Convertible Note Maturity as Part of the August 2023 Azer-cel Deal
Brief: Precision Biosciences Announces Investigational New Drug Clearance By Partner TG Therapeutics For Investigation Of Azer-Cel For Multiple Sclerosis